• A1 and CXCR4 Targeting in Colorectal Cancer

  2026-08-17

  Khorramdelazad et al. evaluated A1, a fluorinated CXCR4 inhibitor, through molecular simulation, CT-26 cell assays, and a syngeneic colorectal cancer model. A1 showed more favorable simulated CXCR4 binding than AMD3100 and produced stronger antitumor, anti-migratory, and tumor-microenvironment effects in the reported preclinical systems.

• Cytarabine (AraC): Mechanism and Research Use

  2026-08-17

  Cytarabine, also called AraC, is a deoxycytidine-related nucleoside analog that inhibits DNA synthesis after intracellular phosphorylation. Its value in leukemia research comes from the direct connection between dCK activation, polymerase inhibition, apoptosis, and measurable resistance phenotypes.

• DEV VP26 Maps an Actin–Myosin II Host Network

  2026-08-16

  This study combines VP26 affinity purification, proteomics, interaction validation, and functional perturbation to identify the host actin–myosin II network as a determinant of duck enteritis virus proliferation. Its findings nominate MYH9 as an important host factor and provide a framework for testing how cytoskeletal machinery supports herpesvirus infection.

• Mc-Val-Cit-PABC-PNP ADC Linker Guide

  2026-08-15

  Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable peptide linker for research workflows involving antibody-drug conjugate synthesis and lysosomal payload release. It is supplied as a solid, dissolves in DMSO, and should not be treated as a water- or ethanol-compatible reagent or as a diagnostic, therapeutic, or medical product.

• H4K12 Lactylation Drives TNBC via SLFN5 Loss

  2026-08-14

  The reference study identifies histone H4K12 lactylation as a metabolic-to-epigenetic mechanism that promotes triple-negative breast cancer progression by suppressing SLFN5. Its combination of tissue analysis, metabolic perturbation, chromatin profiling, reporter assays, and rescue experiments provides a practical framework for studying lactate-dependent gene regulation in cancer metabolism research.

• GW4064: FXR Activation in Metabolic Research

  2026-08-14

  GW4064 is a non-steroidal FXR agonist for resolving how nuclear-receptor signaling shapes bile acid, cholesterol, and triglyceride biology. Its value extends to mechanistic fibrosis workflows, where controlled FXR activation can be paired with TLR4, collagen, and ferroptosis readouts.

• Nitrocefin B6052: Reliable β-Lactamase Assays

  2026-08-13

  Learn how Nitrocefin (SKU B6052) can distinguish β-lactamase activity from cell viability effects, improve assay controls, and support antibiotic-resistance research. This scenario-driven guide covers compatibility, preparation, data interpretation, and practical supplier selection using product specifications and current literature.

• SAR405 for Reliable Vps34 and Autophagy Assays

  2026-08-13

  This scenario-based guide explains how SAR405 (SKU A8883) can improve interpretation of viability, proliferation, and autophagy experiments by selectively perturbing Vps34 rather than broadly inhibiting PI3K signaling. It covers assay design, solvent handling, readout selection, energy-stress confounders, and practical product-selection criteria.

• CCCP: A Mitochondrial Morphology Challenge Tool

  2026-08-12

  CCCP, or carbonyl cyanide m-chlorophenyl hydrazine, is more than an oxidative phosphorylation inhibitor: it can serve as a controlled energetic stressor for interpreting mitochondrial morphology assays. This article connects CCCP challenge design with deep-learning analysis of urine-derived stem cells in Alzheimer’s research.

• seRNA-NPCm Drives NPC Metastasis via NPM1/c-Myc/NDRG1

  2026-08-12

  The 2023 reference study identifies a carcinogen-induced super-enhancer RNA, seRNA-NPCm, as a regulatory driver of nasopharyngeal carcinoma metastasis. By integrating transcriptomic, nascent-transcription, chromatin, perturbation, and patient-validation approaches, the authors connect seRNA-NPCm to NDRG1 activation through an NPM1/c-Myc-dependent enhancer–promoter mechanism.

• MVC Uses RhoA/ROCK1 to Open Tight Junctions

  2026-08-11

  Ren et al. identify a direct interaction between the MVC capsid protein VP2 and ROCK1 and show that MVC activates the RhoA/ROCK1/MLC2 axis in canine WRD cells. The resulting actomyosin contraction redistributes Occludin, increases barrier permeability, and supports viral infection, highlighting host signaling and tight-junction regulation as potential antiviral intervention points.

• Lisinopril Dihydrate: Applied ACE Workflows

  2026-08-10

  Lisinopril dihydrate is a water-compatible, long-acting ACE inhibitor for controlled studies of renin–angiotensin signaling. This guide connects mechanism-focused assays with practical workflows for hypertension research, heart failure research, acute myocardial infarction research, and diabetic nephropathy models, including troubleshooting for reproducible dosing and interpretation.

• Isotoosendanin Targets SHP-2 in NSCLC

  2026-08-08

  A September 2024 study reports that isotoosendanin suppresses NSCLC growth in cell and nude-mouse models by binding SHP-2, reducing its ubiquitination, and inhibiting JAK/STAT3 signaling. Its use of target prediction, orthogonal binding assays, ubiquitination analysis, and rescue experiments provides a mechanistic framework for evaluating this phytochemical, while its preclinical design leaves questions about selectivity, pharmacology, and clinical translation.

• Salmonella Haem and Macrophage Phagocytosis

  2026-08-07

  This Nature Microbiology study identifies SirM-mediated methylation of HemL as a mechanism that increases Salmonella haem production and suppresses macrophage phagocytosis. The work connects bacterial haem metabolism with Cdc42 inhibition, macrophage death, and enhanced virulence in mice, broadening the interpretation of haem biosynthesis beyond iron acquisition.

• ML385: Selective NRF2 Inhibitor Empowering Translational Res

  2026-08-07

  ML385 enables precise and reproducible NRF2 pathway inhibition across cancer, inflammation, and oxidative stress research. Its robust selectivity and validated performance underpin advanced experimental designs, overcoming common challenges in therapeutic resistance and mechanistic dissection.

7996 records 9/534 page Previous Next First page 上5页 678910 下5页 Last page